Esperion Therapeutics (ESPR) Stock Price, News & Analysis

Company Overview

Esperion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S. Food and Drug Administration, and NILEMDO (bempedoic acid/ezetimibe), an oral fixed-dose combination therapy. Both products are indicated as adjuncts to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Esperion continues to explore additional formulations and indications for its ACL inhibition platform, with clinical programs aimed at expanding patient access and optimizing long-term cardiovascular outcomes.

Headquartered in Ann Arbor, Michigan, Esperion was re-established in 2013 following the acquisition of specific cardiovascular assets from a global pharmaceutical company. The company completed its initial public offering on the NASDAQ Global Market under the ticker symbol “ESPR” and maintains research, development and commercial operations in the United States. Esperion has also pursued regulatory approvals and market launches in Europe, working to broaden its geographic footprint and engage with healthcare providers and payers worldwide.

Esperion’s leadership team is led by President and Chief Executive Officer Timothy M. Mayleben, who brings extensive experience in commercial strategy and product launches within the cardiovascular therapeutic area. Under this leadership, the company aims to further develop its pipeline, enhance patient outreach and drive adoption of oral LDL-C–lowering treatments to address the significant unmet needs in cardiovascular health management.

Key Stats

• Today's Range: $2.75 to $2.75
• 50-Day Range: $1.12 to $2.84
• 52-Week Range: $0.69 to $3.94
• Volume: 9,016 shs
• Average Volume: 4.94 million shs
• Market Capitalization: $557.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Esperion Therapeutics Stock Analysis - MarketRank™

Esperion Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 260th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Esperion Therapeutics has a consensus price target of $7.00, representing about 153.2% upside from its current price of $2.77.

Amount of Analyst Coverage

Esperion Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Esperion Therapeutics is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Esperion Therapeutics is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Esperion Therapeutics has a PEG Ratio of 62.22. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.35% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Esperion Therapeutics has recently decreased by 1.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Esperion Therapeutics does not currently pay a dividend.

Dividend Growth

Esperion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.76

Percentage of Shares Shorted

11.35% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Esperion Therapeutics has recently decreased by 1.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Esperion Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 12 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

MarketBeat Follows

5 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,486.00 in company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Esperion Therapeutics is held by insiders.

Percentage Held by Institutions

47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESPR Stock Analysis - Frequently Asked Questions

How have ESPR shares performed this year?

Esperion Therapeutics' stock was trading at $2.20 on January 1st, 2025. Since then, ESPR stock has increased by 25.7% and is now trading at $2.7650.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Tuesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The biopharmaceutical company earned $82.39 million during the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative trailing twelve-month return on equity of 0.91%.
Read the conference call transcript.

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' top institutional shareholders include Wasatch Advisors LP (5.22%), Two Seas Capital LP (5.02%), Marshall Wace LLP (2.68%) and Geode Capital Management LLC (2.31%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker, Sheldon L Koenig, Eric Warren, Joanne M Foody and J Martin Carroll.
View institutional ownership trends.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ESPR
• CIK: 1434868
• Web: www.esperion.com
• Phone: (734) 887-3903
• Fax: N/A
• Employees: 200
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Esperion Therapeutics: $7.00
• High Price Target: $16.00
• Low Price Target: $3.00
• Potential Upside/Downside: +157.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 62.22
• Net Income: -$51.74 million
• Net Margins: -35.84%
• Pretax Margin: -38.80%
• Return on Equity: -0.91%
• Return on Assets: -28.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $332.31 million
• Price / Sales: 1.65
• Cash Flow: $0.02 per share
• Price / Cash Flow: 115.29
• Book Value: ($1.97) per share
• Price / Book: -1.38

Miscellaneous

• Outstanding Shares: 201,620,000
• Free Float: 198,195,000
• Market Cap: $548.41 million
• Optionable: Optionable
• Beta: 0.89